As of September 30, 2026, Perspective Therapeutics, Inc. carries a market capitalization of 273.53M, placing it among publicly traded companies globally. Its enterprise value stands at 98.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 273.53M |
| Enterprise Value | 98.82M |
Perspective Therapeutics, Inc.'s next confirmed earnings release is scheduled for April 1, 2027.
| Earnings Date | 4/1/2027 |
As of September 30, 2026, Perspective Therapeutics, Inc. has 114.16M shares outstanding.
| Shares Outstanding | 114.16M |
These figures are as of September 30, 2026.
| PB Ratio | 1.05 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | -2.05 |
| P/OCF Ratio | -2.63 |
As of September 30, 2026, Perspective Therapeutics, Inc. maintains a current ratio of 5.18, meaning it holds 5.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.25, indicating moderate leverage, while an interest coverage ratio of -320.46 demonstrates limited ability to service its debt obligations.
| Current Ratio | 5.18 |
| Quick Ratio | 5.09 |
| Debt / Equity | 1.25 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | -320.46 |
Over the twelve months ended September 30, 2026, Perspective Therapeutics, Inc. posted a negative return on equity (ROE) of -45.78, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -37.22, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 166.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -45.78 |
| Return on Assets (ROA) | -37.22 |
| Employee Count | 166.00 |
As of the close on November 17, 2026, Perspective Therapeutics, Inc.'s stock has declined approximately 54.73% over the past 52 weeks. The 50-day moving average sits at 1.79, while the 200-day moving average is 2.93.
| 52-Week Price Change | -54.73% |
| 50-Day Moving Average | 1.79 |
| 200-Day Moving Average | 2.93 |
Over the twelve months ended September 30, 2026, Perspective Therapeutics, Inc. generated - - in revenue and converted that into -108.44M in net income, yielding earnings per share of -1.04. EBITDA reached -112.25M, while operating income came in at -116.19M.
| Operating Income | -116.19M |
| Pretax Income | -109.31M |
| Net Income | -108.44M |
| EBITDA | -112.25M |
| EBIT | -116.19M |
| Earnings Per Share (EPS) | -1.04 |
As of September 30, 2026, Perspective Therapeutics, Inc. holds 177.96M in cash and equivalents against 3.25M in total debt, resulting in a net debt position of -34.81M. Total book value stands at 260.00M, with working capital of 146.18M providing operational flexibility.
| Cash & Cash Equivalents | 177.96M |
| Total Debt | 3.25M |
| Net Debt | -34.81M |
| Equity (Book Value) | 260.00M |
| Book Value Per Share | 2.28 |
| Working Capital | 146.18M |
Perspective Therapeutics, Inc. produced -95.40M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -27.05M in capital expenditures, free cash flow totaled -122.45M - equivalent to -1.17 per share.
| Operating Cash Flow | -95.40M |
| Capital Expenditures | -27.05M |
| Free Cash Flow | -122.45M |
| FCF Per Share | -1.17 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -48.75: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -53.12, meaning Perspective Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -53.12 |
| FCF Yield | -48.75 |
Perspective Therapeutics, Inc.'s most recent stock split took place on June 17, 2024 with a 10:1 split ratio.
| Last Split Date | 6/17/2024 |
| Split Ratio | 10:1 |
As of September 30, 2026, Perspective Therapeutics, Inc. has an Altman Z-Score of 0.09, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.09 |